Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 8/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CEPT1 | Q9Y6K0 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222684 | 0.89 | S1PR1 (0.48) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL2228824 | 0.88 | S1PR1 (0.42) | S1PR1MAPTLMNARXFP1APP | |
| SCHEMBL2229154 | 0.86 | ESR1 (0.47) | S1PR1ESR1ESR2POLBGAA | |
| SCHEMBL2222186 | 0.85 | S1PR1 (0.48) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL2228881 | 0.85 | ESR1 (0.38) | S1PR1ESR1ESR2APPPOLB | |
| SCHEMBL2225593 | 0.84 | S1PR1 (0.52) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL15966903 | 0.84 | S1PR1 (0.42) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL14797019 | 0.84 | S1PR1 (0.56) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL2225216 | 0.81 | S1PR1 (0.69) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL2224473 | 0.80 | NPC1 (0.40) | S1PR1ESR1ESR2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | claimed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | claimed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | claimed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, CDK2, CCNT2 | S1PR1 1027/4885ESR1 1897/4885ESR2 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.